In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gastroenterology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2008.09.068PMID 18996386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

  2008cited by this paper
• Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

  2008cited by this paper
• Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

  2007cited by this paper
• Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

  2006cited by this paper
• Analysis of the Cytosolic Domains of the Hepatitis B Virus Envelope Proteins for Their Function in Viral Particle Assembly and Infectivity

  2006cited by this paper
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

  2006cited by this paper
• The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations.

  2005cited by this paper
• Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir

  2005cited by this paper
• Role of the Antigenic Loop of the Hepatitis B Virus Envelope Proteins in Infectivity of Hepatitis Delta Virus

  2005cited by this paper
• Quantification of Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates Different Patterns of Virological Response to Interferon Therapy in Chronically Infected Patients

  2005cited by this paper
• Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection.

  2005cited by this paper
• Failure of the Lamivudine-Resistant rtM204I Hepatitis B Virus Mutants To Efficiently Support Hepatitis Delta Virus Secretion

  2005cited by this paper
• Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

  2004cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

  2003cited by this paper
• Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

  2003cited by this paper
• The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.

  2002cited by this paper
• Infection of a human hepatoma cell line by hepatitis B virus

  2002cited by this paper
• Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.

  2002cited by this paper
• Mutations of the Woodchuck Hepatitis Virus Polymerase Gene That Confer Resistance to Lamivudine and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil

  2002cited by this paper
• Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy.

  2001cited by this paper
• Hepatitis B virus assembly is sensitive to changes in the cytosolic S loop of the envelope proteins.

  2000cited by this paper
• Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.

  1999cited by this paper
• Emergence of Drug-Resistant Populations of Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral Nucleoside Lamivudine

  1999cited by this paper
• Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

  1997cited by this paper
• Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain.

  1994cited by this paper
• The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus

  1994cited by this paper
• Molecular Biology of the Hepatitis B Virus

  1991cited by this paper
• Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification

  1990cited by this paper
• Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen

  1989cited by this paper
• Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope

  1986cited by this paper

• Surface Gene Mutations of Hepatitis B Virus and Related Pathogenic Mechanisms: A Narrative Review

  2025cites this paper
• Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients

  2025cites this paper
• Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis

  2023cites this paper
• Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D.

  2022cites this paper
• Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study

  2021cites this paper
• 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplantation

  2021cites this paper
• Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.

  2021cites this paper
• Entecavir‐resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization

  2020cites this paper
• Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.

  2019cites this paper
• Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients

  2019cites this paper
• Prevalence of the entecavir‐resistance‐inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients

  2019cites this paper
• The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection.

  2018cites this paper
• Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model

  2018cites this paper
• Statistical analysis of sequence populations in virology and immunology (Statistische Analyse von Sequenzpopulationen in der Virologie und Immunologie)

  2017cites this paper
• Different antiviral effects of IFNα and IFNβ in an HBV mouse model.

  2017cites this paper
• Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults.

  2017cites this paper
• Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs

  2017cites this paper
• Translational Medicine in Hepatitis B Virus: What Can We Learn from Clinical Samples?

  2016cites this paper
• The prevalence of mutations in the major hydrophilic region of the surface antigen of hepatitis B virus varies with subgenotype

  2015cites this paper
• Tenofovir‐based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir

  2015cites this paper
• Strategies to inhibit entry of HBV and HDV into hepatocytes.

  2014cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

  2014cites this paper
• A simple and efficient strategy for the de novo construction of greater-than-genome-length hepatitis B virus replicons.

  2014cites this paper
• Selected Phenotypic Assays Used to Evaluate Antiviral Resistance and Viral Fitness of Hepatitis B Virus and Its Variants

  2014cites this paper
• Safe and cost-effective control of post-transplantation recurrence of hepatitis B

  2014cites this paper
• N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape.

  2014cites this paper
• Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

  2013cites this paper
• The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.

  2013cites this paper
• Application of mass spectrometry to molecular diagnostics of viral infections

  2013cites this paper
• Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance

  2013cites this paper
• The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies

  2013cites this paper
• Multidrug‐resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy

  2013cites this paper
• Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.

  2013cites this paper
• Hepatitis B virus wild‐type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir‐based regimen

  2013cites this paper
• Selection of chronic hepatitis B therapy with high barrier to resistance.

  2012cites this paper
• Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.

  2012cites this paper
• Viral fitness: definitions, measurement, and current insights

  2012cites this paper
• Are novel combination therapies needed for chronic hepatitis B?

  2012cites this paper
• Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome

  2012cites this paper
• Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.

  2012cites this paper
• Management of treatment failure in chronic hepatitis B.

  2012cites this paper
• Antiviral therapies: focus on hepatitis B reverse transcriptase.

  2012cites this paper
• Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.

  2012cites this paper
• The impact of lamivudine-based antiretroviral therapy on hepatitis B virus (HBV) genetic evolution among HIV-HBV co-infected patients

  2012cites this paper
• Experimental models and therapeutic approaches for HBV

  2012cites this paper
• The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.

  2012cites this paper
• Brain-Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders

  2012cites this paper
• off-treatment response is necessary to prevent both liver damage and the long-term complications of chronic hepatitis

  2012cites this paper
• Potent Inhibition of Late Stages of Hepadnavirus Replication by a Modified Cell Penetrating Peptide

  2012cites this paper
• The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.

  2011cites this paper
• Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients.

  2011cites this paper
• Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy

  2011cites this paper
• Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.

  2010cites this paper
• Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue‐experienced Chinese patients with chronic HBV infection

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Hepatitis B virus: from diagnosis to treatment.

  2010cites this paper
• The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.

  2010cites this paper
• Drug resistance in antiviral therapy.

  2010cites this paper
• Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B

  2010cites this paper
• Molecular Genetics of HBV Infection

  2010cites this paper
• Therapie der chronischen Hepatitis B: Resistenzmechanismen gegen Hemmer der HBV-Polymerase

  2009cites this paper
• TreatmentofhepatitisB virus-infectedpatients:utility oftherapeuticrecommendations indevelopingcountries

  2009cites this paper
• Traitement de l’hépatite B : progrès attendus Treatment of hepatitis B: New perspectives

  2009cites this paper
• Traitement de l’hépatite B : progrès attendus

  2009cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

  2009cites this paper
• Differential Impact of Immune Escape Mutations G145R and P120T on the Replication of Lamivudine-Resistant Hepatitis B Virus e Antigen-Positive and -Negative Strains

  2009cites this paper
• Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral Therapy

  2009cites this paper
• Pathobiology of HBV mutants and clinical impact for treatment monitoring

  2009cites this paper
• Hepatitis B virus resistance to nucleos(t)ide analogues.

  2009cites this paper
• Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries

  2009cites this paper
• [Treatment of hepatitis B: new perspectives].

  2009cites this paper
• World Journal of Hepatology

  year unknowncites this paper
• Fitness and infectivity of drug-resistant and cross-resistant HBV mutants : why and how is it studied ?

  year unknowncites this paper
• Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes

  year unknowncites this paper
• Infection and Drug Resistance Dovepress New Strategies for the Treatment of Hepatitis C Virus Infection and Implications of Resistance to New Direct-acting Antiviral Agents Jaume Guardia

  year unknowncites this paper